SUO 2021: Molecular Subtyping to Stratify the Treatment of Muscle-Invasive Bladder Cancer: A Cost-Effectiveness Analysis

Society of Urologic Oncology 2021, Neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), cost-effectiveness of molecular subtyping in the management of MIBC, incremental cost-effectiveness ratio (ICER).

Read the full article here

Related Articles